About GeNEWityTM


Genewity B.V. is a recently founded biotech company based in Leiden, the Netherlands. Closely collaborating with the LUmc, we build on successes of our scientific and business teams in cell and gene therapies.

GenewityTM has been founded to commercialize another potentially groundbreaking therapy for developing autologous thymus tissue de novo. GenewityTM is currently in a preclinical development stage and is engaged in raising a Series A to push the technology to the clinic.

Genewity is a partner in the PRO-THYMUS Eureka Eurostars 3 Programme. Please visite the Eureka website for more information.

Genewity has been selected for funding under the European Innovation Council (EIC) Accelerator program.

Genewity has received co-funding through the PPP Allowance made available by Health-Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships.

Our team members

Arno Bisschop, PhD, MD.
Chief Executive Officer

Prof. Dr. Frank Staal
Chief Scientific Advisor

Prof. Dr. Eric Claassen
Chief Scientific Officer

Max Renes, MPhil, MSc.
Chief Operating Officer

Conny Kruyssen
Chief Financial Officer

Rob Posthumus, LL.M.
Chief Legal Officer

Jelle Feddema, MSc.
Head of Business Dev.

Drs. Johan Renes
Intellectual Property Strategy Advisor

Hadil Es-Sbai, MSc.
Clinical Development Advisor

Linda van de Burgwal, PhD.